新诊断淋巴瘤患者抗磷脂抗体的高发生率和抗磷脂抗体预测评分的提出。
High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score.
机构信息
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
出版信息
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620928392. doi: 10.1177/1076029620928392.
Given that the presence of antiphospholipid (aPL) antibodies has been proposed to be associated with thrombosis in newly diagnosed patients with lymphoma, we conducted a prospective cohort study on these patients. In all, 154 patients were enrolled. More than half were advanced-stage diffuse large B-cell lymphoma. Approximately one-third (35.7%) of the patients had the presence of aPLs, with single-, double-, and triple-aPL positivities of 29.9%, 5.2%, and 0.6%, respectively. Of the 154 patients, 8 (5.19%) developed symptomatic thrombosis during follow-up. There were no significant differences in the incidences of thrombosis for the aPL-positive and aPL-negative groups (5.5% vs 5.1%; = 1.000). In a multivariate analysis, patients with male sex and lymphoma stage IV were significant risk factors for aPL positivity, with odds ratio [OR] = 2.22 (95% CI: 1.11-4.45), = .025, and OR: 2.34 (95% CI: 1.17-4.67), = .016, respectively. An aPL predictive score of ≥-1 was predictive of aPL positivity, with a sensitivity of 83.6% and specificity of 34.3%.
鉴于抗磷脂 (aPL) 抗体的存在与新诊断的淋巴瘤患者的血栓形成有关，我们对这些患者进行了一项前瞻性队列研究。共有 154 名患者入组。超过一半为晚期弥漫性大 B 细胞淋巴瘤。约三分之一（35.7%）的患者存在 aPL，分别为单阳性、双阳性和三阳性，占比为 29.9%、5.2%和 0.6%。在 154 名患者中，有 8 名（5.19%）在随访期间出现有症状的血栓形成。aPL 阳性组和 aPL 阴性组的血栓形成发生率无显著差异（5.5%比 5.1%； = 1.000）。在多变量分析中，男性和淋巴瘤 IV 期是 aPL 阳性的显著危险因素，优势比 [OR] = 2.22（95%CI：1.11-4.45）， =.025，和 OR：2.34（95%CI：1.17-4.67）， =.016。aPL 预测评分≥-1 预测 aPL 阳性，灵敏度为 83.6%，特异性为 34.3%。
Zotero 插件